Overview

A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gefitinib